The GnRH antagonist protocol, combined with a GnRH agonist for ovulation induction, is now considered by some clinics as a better option for ART due to the reduced risk of ovarian hyperstimulation syndrome (OHSS). The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.